UY37497A - Formulación tópica que comprende n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamida - Google Patents

Formulación tópica que comprende n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamida

Info

Publication number
UY37497A
UY37497A UY0001037497A UY37497A UY37497A UY 37497 A UY37497 A UY 37497A UY 0001037497 A UY0001037497 A UY 0001037497A UY 37497 A UY37497 A UY 37497A UY 37497 A UY37497 A UY 37497A
Authority
UY
Uruguay
Prior art keywords
methyl
pyridinyl
acetamide
phenyl
thiazol
Prior art date
Application number
UY0001037497A
Other languages
English (en)
Inventor
Yogeshwar Bachhav Dr
Tamara Pfaff Dr
Wilfried Schwab Dr
Alexander Birkmann Dr
Original Assignee
Aicuris Anti Infective Cures Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aicuris Anti Infective Cures Gmbh filed Critical Aicuris Anti Infective Cures Gmbh
Publication of UY37497A publication Critical patent/UY37497A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención refiere a formulaciones farmacéuticas de agentes antivirales activos para aplicación tópica, particularmente para uso en tratamiento de infecciones por virus herpes humano, donde los agentes antivirales activos pueden seleccionarse del grupo comprendiendo: hemihidrato de la base libre de N-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-N-metil-2-[4-(2-piridinil)-fenil]-acetamida, la sal maleato de N-[5-(amino-sulfonil)-4-metil-1,3-tiazol-2-il]-N-metil-2-[4-(2-piridinil)fenil]acetamida, la sal de mesilato de N-[5-(amino-sulfonil)-4-metil-1,3-tiazol-2-il]-N-metil-2-[4-(2- piridinil)fenil]acetamida, y la base libre de N-[5-(amino-sulfonil)-4-metil-1,3-tiazol-2-il]-N-metil-2-[4-(2- piridinil)fenil]acetamida. Específicamente, se proporcionan dichas formulaciones farmacéuticas comprendiendo un agente antiviral como se ha descrito anteriormente disuelto o solubilizado, hidroxil tolueno butilado (BHT) y PEG 400 Super RefinedTM a un pH aparente de 4,0 a 5,0, preferiblemente a un pH aparente de 4,0 a 4,5.
UY0001037497A 2016-11-28 2017-11-28 Formulación tópica que comprende n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamida UY37497A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16201005 2016-11-28

Publications (1)

Publication Number Publication Date
UY37497A true UY37497A (es) 2018-06-29

Family

ID=57406185

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001037497A UY37497A (es) 2016-11-28 2017-11-28 Formulación tópica que comprende n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamida

Country Status (4)

Country Link
AR (1) AR110250A1 (es)
TW (1) TW201825095A (es)
UY (1) UY37497A (es)
WO (1) WO2018095576A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA126163C2 (uk) 2017-10-05 2022-08-25 Інновейтів Молекьюлз Ґмбх Енантіомери серії противірусних сполук
TW202038947A (zh) 2018-11-28 2020-11-01 德商創新分子有限責任公司 在與溶瘤病毒之組合療法中治療癌症的解旋酶引子酶抑制劑
CN115348859A (zh) 2020-03-26 2022-11-15 艾库里斯有限责任两合公司 包含n-[5-(氨基磺酰基)-4-甲基-1,3-噻唑-2-基]-n-甲基-2-[4-(2-吡啶基)苯基]乙酰胺半水合物的眼用配制剂
EP3925595A1 (en) * 2020-06-17 2021-12-22 AiCuris GmbH & Co. KG Ophthalmic formulation comprising n-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl] acetamide hemihydrate
EP4172163A4 (en) * 2020-06-30 2024-07-24 Dermira Inc IRAK4 INHIBITORS AND TOPICAL USES THEREOF

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DOP2000000109A (es) 1999-12-23 2002-08-30 Gerald Kleymann Derivados de tiazolilamida
DE10129716A1 (de) * 2001-06-22 2003-01-02 Bayer Ag Kombinationspräparate zur Herpes-Behandlung
DE10129714A1 (de) 2001-06-22 2003-01-02 Bayer Ag Topische Anwendung von Thiazolylamiden
DE102005014248A1 (de) 2005-03-30 2006-10-05 Aicuris Gmbh & Co. Kg Pharmazeutische Zubereitung von N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamid
ES2442928T3 (es) * 2010-07-08 2014-02-14 Devirex Ag Composiciones de polietilenglicol para controlar las recidivas de herpes labialis, herpes genitalis y herpes zoster
EP2573085A1 (en) 2011-09-26 2013-03-27 AiCuris GmbH & Co. KG N-[5-(aminosulfonyl)-4methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl] acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range
EP2573086A1 (en) * 2011-09-26 2013-03-27 AiCuris GmbH & Co. KG N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate

Also Published As

Publication number Publication date
AR110250A1 (es) 2019-03-13
WO2018095576A1 (en) 2018-05-31
TW201825095A (zh) 2018-07-16

Similar Documents

Publication Publication Date Title
UY37497A (es) Formulación tópica que comprende n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamida
CL2018003291A1 (es) Amidas heterocíclicas útiles como moduladores de proteínas (divisional de solicitud cl 2850-2018).
CR20170411A (es) Composiciones farmacéuticas que comprenden n-(3,5-dimetoxifenil)-n-(1-metiletil)-n-[3-(1-metil-1h-pirazol-4-il-quin oxalin-6-il]etano-1,2-diamina
UY37496A (es) Hemihidrato de la base libre de n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamida, métodos de fabricación y usos del mismo
CL2017002939A1 (es) Composiciones farmacéuticas tópicas
BR112013006953A2 (pt) composto, composições farmacêutica e anti-helmíntica, uso de um composto, kit, e, método de tratamento de uma doença
EP4374851A3 (en) Ophthalmic composition for treatment of dry eye disease
WO2016042163A3 (en) Ophthalmic drug compositions
CU23423B7 (es) Oxazolidinonas sustituidas y su uso en el campo de la coagulación sanguínea
AR055363A1 (es) Formulaciones farmaceuticas que comprenden un beta 2- agonista de accion prolongada para administracion por nebulizacion
CL2018000033A1 (es) Composición para destapar una nariz tapada que tiene actividad antiviral.
BRPI0822162B8 (pt) composição farmacêutica para tratamento tópico de doença das unhas ou leito ungueal
EA201991299A1 (ru) Приготовление твердых циклодекстриновых комплексов для доставки офтальмологических активных фармацевтических ингредиентов
MA56547A (fr) Formulations d'agents pénétrants transdermiques contenant du cannabidiol
BR112014017780A8 (pt) Compostos de sulfona tricíclicos e métodos para fazer e usar os mesmos
PE20071231A1 (es) Formulaciones farmaceuticas de pleconaril
BR112017022521A2 (pt) agente para controlar doenças em plantas de cereais, método para controlar doenças em plantas de cereais, uso de fluoroimida ou um sal agroquimicamente aceitável da mesma, uso de um ou mais compostos, e uso de fluoroimida ou um sal agroquimicamente aceitável da mesma
PE20181522A1 (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
MX2023006235A (es) Composiciones para administracion de farmacos y metodos de uso de las mismas.
AR086491A1 (es) Composicion farmaceutica que comprende fexofenadina
MA40847A (fr) Association comprenant de la spiruline et du palmitoyléthanolamide et/ou des sels ou des dérivés pharmaceutiquement acceptables de ceux-ci et leurs formulations, pour une utilisation dans la prévention et/ou le traitement d'états d'hyperactivité des tissus
JP2016511246A5 (es)
BR112012016549A2 (pt) piperazinas como agentes antimalariais
CO2022002493A2 (es) Nanoemulsion de ácido 18p-glicirretínico
BR112015019744A2 (pt) composições oftálmicas aquosas tópicas contendo um derivado de 1h-indol-1-carboxamida e uso das mesmas para o tratamento de doença oftálmica

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20230705